Jump to content
SCLERO.ORG
Sclero Forums

Search the Community

Showing results for tags 'dmards'.

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


Forums

  • Worldwide
    • Welcome: Guidelines and FAQs
    • Sclero Forums (MAIN)
    • UK Scleroderma
    • News
    • Personal Support

Blogs

  • CFM Babs from Chorley FM
  • barefut impressions
  • My Two Cents...
  • Amanda Thorpe's Blog
  • Joelf's Blog
  • Michael Thorpe's Blog

Find results in...

Find results that contain...


Date Created

  • Start

    End


Last Updated

  • Start

    End


Filter by number of...

Joined

  • Start

    End


Group


Location

Found 13 results

  1. COVID-19 in Patients with Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and DMARDs on Clinical Outcomes. Further work is needed to understand whether immunomodulatory therapies affect COVID-19 incidence. PubMed, Arthritis Rheumatol, 07/28/2020. (Also see DMARDs) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  2. Novartis halts malaria drug trial against COVID-19 amid participant shortfall. Novartis is halting its trial of malaria drug hydroxychloroquine against COVID-19 after struggling to find participants, as data emerged from other studies raising doubts about its efficacy. Reuters Health, 06/19/2020. (Also see DMARDs) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  3. Comparative Risk of Cardiovascular Events (MACE) With Biologic and Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) in Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Based on meta-analysis, as compared to tumor necrosis factor inhibitors, tocilizumab may be associated with a reduced risk of MACE, whereas csDMARDs may be associated with an increased risk of MACE and stroke. PubMed, Arthritis Care Res (Hoboken), 2020 Apr;72(4):561-576. (Also see DMARDs and Treatments for Rheumatoid Arthritis) This item was posted in the ISN Newsroom.
  4. Retinal Complications in Patients with Systemic Lupus Erythematosus Treated with Antimalarial Drugs. Just over 5% of patients developed antimalarial retinal complications, over an average of 12.8 years, but no cases were detected in the first 5 years of therapy. PubMed, J Rheumatol, 2020 Apr;47(4):553-556. (Also see Symptoms and Complications of Lupus and DMARDs) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  5. Clinical and Structural Efficacy of Hydroxychloroquine (HCQ) in Rheumatoid Arthritis (RA): A Systematic Review. Combining HCQ with other DMARDs could provide some clinical improvement in patients with RA. PubMed, Arthritis Care Res (Hoboken), 2020 Jan;72(1):36-40. (Also see Treatments for Rheumatoid Arthritis and DMARDs) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  6. Effects of Sarilumab on Rheumatoid Arthritis (RA) as Reported by Patients Using the Rheumatoid Arthritis Impact of Disease (RAID) Scale. Based on the RAID, sarilumab + csDMARD or as monotherapy reduced the effect of RA on patients' lives to a greater extent than placebo + csDMARD or adalimumab monotherapy. PubMed, J Rheumatol, 2019 Oct;46(10):1259-1267. (Also see Treatments for Rheumatoid Arthritis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  7. Tocilizumab and the Risk of Cardiovascular Disease (CVD): Direct Comparison Among Biologic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis (RA) Patients. Tocilizumab was associated with a CVD risk comparable to that for etanercept as well as a number of other biologics used for the treatment of RA. PubMed, Arthritis Care Res (Hoboken), 2019 Aug;71(8):1004-1018. (Also see Treatments for Rheumatoid Arthritis and Clinical Trials) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  8. Effect of disease-modifying anti-rheumatic drugs (DMARDs) on bone structure and strength in psoriatic arthritis (PsA) patients. Despite longer disease duration, bDMARD-treated PsA patients benefit from higher bone mass and better bone strength than PsA patients receiving methotrexate or no DMARDs. PubMed, Arthritis Res Ther, 2019 Jul 3;21(1):162. (Also see Psoriasis and Psoriatic Arthritis and Disease-Modifying Anti_Rheumatic Drugs) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  9. The effects of methotrexate (MTX) and hydroxychloroquine (HCQ) combination therapy vs methotrexate monotherapy in early rheumatoid arthritis (RA) patients. In contrast to indirect comparison review data, MTX–HCQ seems somewhat more effective after 6 months than MTX monotherapy in early RA patients. Rheumatology, 09/06/2018. (Also see Treatments for Rheumatoid Arthritis and DMARDs) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  10. Ability of disease–modifying antirheumatic drugs to prevent or delay rheumatoid arthritis (RA) onset: a systematic literature review and meta–analysis (MA). This MA demonstrates that early therapeutic intervention may significantly reduce the risk of RA onset in this very first phase of the disease. PubMed, Ann rheumatologist Dis, 06/08/2018. (Also see Treatments for Rheumatoid Arthritis and DMARDs) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  11. The risk of malignancy and its incidence in early rheumatoid arthritis (RA) patients treated with biologic DMARDs. In early RA patients, bDMARD use decreases the overall risk of developing malignancies; however, it does not affect the risk of developing hematologic malignancies. PubMed, Arthritis Res Ther, 2017 Dec 15;19(1):277. (Also see DMARDs and Treatments for Rheumatoid Arthritis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  12. Dosing down and then discontinuing biologic therapy (bDMARD) in rheumatoid arthritis (RA): a review of the literature. In patients who have achieved low disease activity or remission, down–titration and discontinuation of bDMARD therapy may be attempted, with careful monitoring. PubMed, Int J rheumatologist Dis, 12/04/2017. (Also see Treatments for Rheumatoid Arthritis and DMARDs) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
  13. Metabolic and cardiovascular benefits of hydroxychloroquine (HCQ) in patients with rheumatoid arthritis (RA) : a systematic review and meta–analysis. HCQ may benefit the metabolic profile and to a lesser extent cardiovascular events in patients with RA, which suggests its usefulness combined with other conventional synthetic disease–modifying antirheumatic drugs. PubMed, Ann rheumatologist Dis, 09/25/2017. (Also see DMARDs and Treatments for Rheumatoid Arthritis) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and oth
×
×
  • Create New...